5 completed, 1 approved for marketing. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow CONKO-Studiengruppe: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy With or Without Enoxaparin in Pancreatic Cancer enoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy - Pancreatic Cancer | Phase 2 / Phase 3 | Completed | CONKO-Studiengruppe | 312 | 2004-04-01 | 2015-01-08 |
| Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer Enoxaparine - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | CONKO-Studiengruppe | 19 | 2003-01-01 | 2013-09-19 |
| Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer Gemcitabine, Cisplatin, 5-FU - Esophageal Cancer | Phase 2 | Completed | CONKO-Studiengruppe | 92 | 2002-07-01 | 2008-09-26 |
| Parenteral Nutrition Support for Patients With Pancreatic Cancer parenteral nutrition - Cancer Cachexia, Pancreatic Cancer | Phase 2 | Completed | CONKO-Studiengruppe | 32 | 2002-01-01 | 2009-06-12 |
| Gemcitabine (GFF) in Patients With Pancreatic Cancer gemcitabine, folinic acid, 5-FU - Metastatic Pancreatic Cancer | Phase 2 | Completed | CONKO-Studiengruppe | 78 | 1997-09-01 | 2009-06-12 |
| A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 OFF in experimental arm - Pancreatic Cancer | Approved for marketing | CONKO-Studiengruppe | 2009-06-15 |
Pancreatic Neoplasms (5) · Esophageal Neoplasms (1) · Hyperphagia (1) · Thromboembolism (1)
Fluorouracil (4) · Gemcitabine (3) · Leucovorin (3) · Cisplatin (2) · Enoxaparin (2) · Drug Therapy (1) · Heparin, Low-Molecular-Weight (1) · Oxaliplatin (1) · Parenteral Nutrition (1)
Germany (5)
Hanno Riess, MD, PhD (1) · Hanno Riess, PHD (1) · Helmut Oettle, PD (1) · Uwe Pelzer, MD (1)